Eram Khan

1 month ago | mondaq.com | Andrew Lacy |Sarah Jordan |Elliot Silver |Eram Khan

The last year (and particularly the last few months) of theBiden Administration brought a flurry of activity from the FederalTrade Commission (FTC) in the life sciences space, continuing ayearslong pattern of close scrutiny and culminating most notably inthe issuance of a complaint against the leading pharmacy benefitmanagers (PBMs).